Replies to post #799059 on NorthWest Biotherapeutics Inc (NWBO)

[StonkMaster]

Ok Dennis. To each their own.

[Kap10jak]

There has to already be C suites owned by other companies so once approved and installed in Sawston what's to stop renting space elsewhere and slapping in a few Flaskworks units and have Advent employees produce DCVax-l in different locations. I think LP hinted something like that recently about setting up agreements at various hospitals. They could ramp up the production volume of DCVax rapidly.

[KevGee59]

What is not factual:
Taking that old theoretical manual capacity and magically doubling it to “~1000 patients per year” by assuming a Grade C lab will automatically add the same output.

This is what yesterday's PR said: "The Company anticipates that the manufacturing capacity of the first Grade C suite will more than double the aggregate capacity of the existing Grade B manufacturing suites combined.

So if a previous 10Q said they expect/projected around 45-50 patients per month for B Suites...not sure if that was 2 B suites combined, or 1 B suite....the C suite should more than double that combined. Don't you think? Fair question. I was just trying to get a view of how many patients the C Suite might produce. Not looking to argue.